This study investigates the response of bone marrow (particularly megakaryocytes) in mice under the influence of diclofenac sodium for 10 days using intraperitoneal injection at various doses. A fundamentally new immunomagnetic separation method was applied during the experiment, which helped obtain pure lines of bone marrow cells, particularly megakaryocytes (MC), without admixtures of other cells or their particles. The resulting cells completely retain their structure and can be used in further research. The study determined that different doses of diclofenac sodium have different effects on different groups of diabetes mellitus cells CD34-megakaryocytes. The use of 1.0 mg/ml sharply negatively affects the state of early populations of megakaryocytes (decrease by 80%, p=0.05), a dose of 0.025 mg/ml had the least effect on this population of cells (22.8%, p=0.05). The greatest number of average forms of diabetes mellitus 34 was observed when using a dose of 0.95 mg/ml (22.8%, p=0.05), with a gradual decrease in the dose, the indicator of this group of cells decreased. A dose of 0.03 mg/ml did not affect the quantitative state of megakaryocytes, and a dose of 0.025 mg/ml caused a slight decrease (16.6%, p=0.05). Indicators of mature cells of megakaryocytes CD 34- decreased in all studied groups, however, their maximum value reached a maximum decrease by 0.25 mg/ml (55.2%, p=0.05), the dose of diclofenac sodium 0.03 mg/ml, lower (18.4%, p=0.05). Diclofenac sodium in different doses has different effects on the degree of differentiation of CD 34-. Its introduction positively affects the state of intermediate forms of megakaryocytes, except for minimal doses, while the effect on early and mature forms in all cases turned out to be negative.

No abstract

Кровотворна система являє собою популяцію багатьох клітин які виконують в організмі певні функції. Фармацевтична промисловість створює нові препарати з групи не стероїдних протизапальних засобів, але «золотим» стандартом залишається препарат «Диклофенак натрію». При деяких станах людина вимушена приймати цей препарат впродовж тривалого часу, а подекуди пожиттєво. Залишається невстановленим механізм впливу препарату на клітини кісткового мозку за умови тривалого використання. В ході аналізу літератури встановлено, що при вживанні препарату проявляє себе токсична дія на клітини крові та органів кровотворення. Поступово токсична дія зменшується, але тривала дія препарату на організм щура сприяє пригніченню розвитку еритроцитарного та мієлоцитарного ростків кісткового мозку. Оптимальним для використання є період до 10 днів, а потім слід шукати більш безпечніший для організму препарат. Ключові слова: кістковий мозок, Диклофенак натрію, еритроцити, мієлоцити, токсична дія.The hematopoietic system is a population of many cells that perform certain functions in the body. The pharmaceutical industry creates new drugs from the group of nonsteroidal anti-inflammatory drugs, but the "gold" standard remains the drug Diclofenac Sodium. In some conditions, a person is forced to take the drug for a long time, and sometimes all life. The mechanism of the drug effect on the bone marrow cells under the condition of long-term administration remains unclear. In the process of analyzing the literature, it has been established that the use of the drug has a toxic effect on the blood cells and blood-forming organs. Gradually, the toxic effect is reduced, but the long-term effect of the drug on the rat organism contributes to the inhibition of the development of erythrocyte and myelocytic sprouts of the bone marrow. A period of up to 10 days is optimal for use, and then it is worthwhile to look for a drug that is safer for the body.